Fingerprint
Dive into the research topics of 'Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen*, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz
*Corresponding author for this work
- Beckman Research Institute of City of Hope
- Universita Degli Studi Bologna
- Texas A&M University System Health Science Center
- Dana-Farber Cancer Institute
- Jewish General Hospital
- AP-HP Hôpital Saint-Louis
- Institut de Cancerlogie Gustave Roussy
- University of Uppsala
- General Hospital G. Gennimatas
- Fujita Health University
- University Hospital Cologne
- Merck & Co.
- Sylvester Comprehensive Cancer Center
Research output: Contribution to journal › Article › peer-review